China Agrees to Tweaks on Drug Patents as Part of Trade Deal
- Drug companies can seek patent extension for regulator delay
- Provisions mimic some provisions in decades-old U.S. drug law
This article is for subscribers only.
Sign up here to receive the Davos Diary, a special daily newsletter that will run from Jan. 20-24.
China agreed to set up a system to resolve conflicts over drug patents, a move that may help U.S. pharmaceutical companies seeking greater protections for their branded medicine in developing nations.